Cyclopharm makes Technegas®, the only FDA-approved radioactive gas used to diagnose pulmonary embolism — a product with no US competitor and an 85% global market share built over two decades. At A$0.825 versus our fair value of A$0.58, the stock is 42% overvalued. The market is pricing near-certainty of a rapid US rollout; we see a more uncertain path where serial equity dilution erodes per-share value even if the business succeeds.

CYC is best suited to the growth investor with a 3–5 year horizon, a high tolerance for binary outcomes, and the discipline to size the position speculatively (under 2% of portfolio). The structural US opportunity is genuine. The challenge is that at A$0.825, the market has already priced success — leaving growth investors with limited upside and meaningful downside if the rollout takes longer than expected.

Cyclopharm manufactures Technegas®, a radioactive aerosol inhaled by patients before lung scans to diagnose pulmonary embolism. Outside the US, it holds 85% market share across 66 countries and generates a reliable A$14m annual royalty stream. Inside the US — a market roughly ten times larger — it only received FDA approval in 2023 and has since installed the product in 46 hospitals.

FY25 results showed the tension clearly. Revenue grew 17% to A$32.3m as early US sites began generating income, but EBITDA deteriorated to negative A$15.4m as the company invested heavily in its American commercial team. The US segment contributed just A$2.7m in revenue — meaningful progress, but a fraction of what the installed base will eventually produce.

The investment case rests on a single question: how quickly will US hospitals adopt Technegas®? A January 2026 multi-society guideline endorsement — the first clinical update in 13 years — has removed a key adoption barrier. Management is guiding for 250–300 US sites by end of 2026, which would transform the financial profile. We apply a 70% credibility discount to that guidance given one prior miss. The company needs at least one further equity raise to fund losses through to EBITDA breakeven, expected around FY28, and that dilution is a permanent cost that per-share analysis must absorb.

At A$0.825 versus our fair value of A$0.58, the stock is 42% overvalued.

What happened?

FY25 revenue of A$32.3m grew 17%, but the headline masked diverging segments. The ex-US Technegas® royalty stream slipped 3% to A$14m, partly due to AUD appreciation eroding USD receipts. Third-party distribution recovered to A$15.6m after a soft prior year. US Technegas® contributed A$2.7m — small in absolute terms but growing from essentially zero. The cash position fell to A$6.6m by year-end, triggering a A$20m capital raise completed in early 2026.

What's next?

The financial story from here is almost entirely about US site count. Each hospital that installs a Technegas® generator produces roughly A$80,000 in annual consumable revenue at near-90% gross margins. Forty-six sites are currently active. Our base case assumes 200–225 sites by December 2026 — below management's 250–300 guidance, reflecting one prior miss.

The January 2026 multi-society clinical guideline is the single most important near-term catalyst. It embeds Technegas® as the preferred agent for ventilation imaging in standard protocols used by every US nuclear medicine department. Sites already in the procurement pipeline should convert faster as a result.

Two further milestones are worth watching closely. A permanent CMS benefit code — expected in the next 12–18 months — would replace the current transitional reimbursement arrangement and remove the last administrative barrier to adoption. A new patent family application, if granted, could extend US exclusivity from 2031 toward 2041, materially changing the long-term valuation.

The central risk is not competitive — no rational company will spend a decade and hundreds of millions of dollars to enter a US$180m market that Cyclopharm already owns. The real risk is dilution. CYC burns approximately A$17m per year and will need at least one further equity raise before reaching EBITDA breakeven around FY28. Each raise at below-fair-value transfers wealth permanently from existing shareholders to new ones. In the bear case, share count grows from today's 127 million to 165 million; in the severe case, it reaches 195 million. A business that executes perfectly can still produce a poor outcome for the shareholders who owned it during the journey. At A$0.825, the market assigns roughly 85% probability to a clean execution outcome with minimal dilution — a confidence level the evidence does not yet support. The stock becomes analytically interesting below A$0.40, where the risk-reward ratio exceeds 2:1 and failure scenarios are adequately compensated.